Healthcare and Life Sciences Antitrust


February 24, 2022

The Year in Review and a Look Ahead to What You Need to Know for 2022

BRG’s Ruth Tabak and Sheppard Mullin experts Bevin Newman, John Carroll, and David Garcia recapped dramatic developments in antitrust and healthcare policy under the Biden administration and looked ahead to what you need to know for 2022. Topics included:

  • Ongoing overhaul of the federal agencies’ approach to M&A  and merger remedies
  • Increased scrutiny of provider transactions
  • Developments around private equity in healthcare and life sciences
  • Evolving rules on vertical transactions and arrangements
  • New policies on drug pricing and competition
  • Pending legislation targeting antitrust in healthcare

Find out more.

BRG Experts

Related Professionals

Ruth E. Tabak


Washington, DC